

# Challenges in rolling out HIV care and antiretroviral treatment in resource limited settings

Dissertation to be submitted for the degree of Doctor in Medical Sciences at the University of Antwerp to be defended by

**Barbara Castelnovo**

Infectious Diseases Institute,  
College of Health Sciences, Makerere University

PROMOTER

**Robert Colebunders**  
University of Antwerp

Department of  
Clinical Sciences Institute  
of Tropical Medicine, Antwerp  
and Faculty of Medicine Epidemiology  
and Social Medicine, University of Antwerp  
Antwerp 2011





Department of Clinical Sciences, Institute of Tropical Medicine  
and  
Epidemiology and Social Medicine, Faculty of Medicine  
University of Antwerp

**Challenges in rolling out HIV care and antiretroviral  
treatment in resource limited settings**

Dissertation to be submitted for the degree of Doctor in Medical  
Sciences at the University of Antwerp to be defended by  
Proefschrift voorgelegd tot het behalen van de graad van Doctor in  
de Medische Wetenschappen aan de Universiteit Antwerpen te  
verdedigen door

**Barbara Castelnovo**

Infectious Diseases Institute,  
College of Health Sciences, Makerere University

Promotor: Robert Colebunders      Antwerp 2011

# Table of contents

<b>List of acronyms used in the introductory chapters and in the and general discussion.....</b>	<b>6</b>
<b>Samenvatting.....</b>	<b>7</b>
<b>Summary .....</b>	<b>10</b>
<b>Chapter 1. Introduction .....</b>	<b>13</b>
1.1 Epidemiology of HIV in Uganda.....	13
1.1.1. The beginning. A new syndrome: “slim disease”.....	13
1.1.2. The Nineties. HIV prevention: a success story?.....	15
1.1.3 The new millennium: is Uganda losing its grip?.....	20
1.1.4 The present situation .....	22
1.2. The scale up of antiretroviral treatment in Uganda .....	23
1.2.1. 1997-2003. The UNAIDS HIV Drug Access Initiative in Uganda .....	23
1.2.2. The scale up of free ART programs in Uganda .....	24
2.1.3. Present status of ART and patients outcomes in Uganda. ....	26
References.....	28
<b>Chapter 2. Objectives and outline.....</b>	<b>35</b>
References.....	36
<b>Chapter 3. Methods .....</b>	<b>37</b>
3.1. The Infectious Disease Institute, Makerere University, Kampala, Uganda.....	37
3.2. Programs at IDI.....	38
3.3. IDI Longitudinal cohorts.....	39
3.4 Committees for the quality and release of data collected at the Infectious Diseases Institute .....	43
References.....	44
<b>Chapter 4. When to start antiretroviral treatment.....</b>	<b>45</b>
4.1 Introduction.....	45
References.....	47
4.2. Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first three years after antiretroviral therapy in an urban African cohort.....	49
Abstract.....	49
4.2.1 Introduction.....	50
4.2.2. Methods.....	51
4.2.3 Results.....	53
4.2.4. Discussion.....	59
References.....	62
4.3. Improvement of the patient flow in a large urban clinic with high HIV seroprevalence in Kampala, Uganda.....	66
Abstract.....	66
4.3.1. Introduction.....	66
4.3.2. Methods.....	67

4.3.3 Results.....	68
4.3.4. Discussion.....	69
References.....	70
<b>Chapter 5. Which regimens? .....</b>	<b>73</b>
5.1 Introduction.....	73
5.1.1 First line regimen.....	73
5.1.2 Second line regimen.....	74
References.....	75
5.2. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV infected patients: a report of 24 cases in a resource limited setting (Uganda). .....	78
Abstract.....	78
5.2.1. Introduction and background.....	78
5.2.2. Methods.....	79
5.2.3. Results.....	80
5.2.4. Discussion.....	82
References.....	84
5.3. Stavudine toxicity in women is the main reason for treatment change in a 3 year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.....	86
Abstract.....	86
5.3.1. Background.....	86
5.3.2. Methods.....	87
5.3.3. Results.....	89
5.3.4. Discussion.....	93
References.....	95
5.4 Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. ....	99
Abstract.....	99
5.4.1. Introduction.....	99
5.4.2. Methods.....	100
5.4.3. Results.....	102
5.4.4. Discussion.....	109
References.....	111
<b>6. How to monitor ART efficacy and when to switch to second line treatment? .....</b>	<b>115</b>
6.1. Introduction.....	115
6.1.1. Clinical criteria for treatment failure.....	116
6.1.2. Immunologic criteria for treatment failure.....	116
6.1.3. Virologic criteria for treatment failure.....	117
References.....	118
6.2 Can response of a Pruritic Papular Eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?.....	120
Abstract.....	120
6.2.1 Introduction.....	121

6.2.2. Methods.....	122
6.2.3. Results.....	123
6.2.4. Discussion.....	127
References.....	128
6.3.2 High rate of misclassification of treatment failure based on WHO immunological criteria.....	132
6.3.1 Introduction.....	132
6.3.2 Methods.....	132
6.3.3 Results.....	133
6.3.4. Conclusions.....	133
References.....	134
6.4. Evaluation of WHO criteria for viral failure in patients on antiretroviral treatment in resource limited settings.....	135
Abstract.....	135
6.4.1. Introduction.....	136
6.4.2. Methods.....	136
6.4.3. Results.....	138
6.4.4. Discussion.....	143
References.....	146
<b>Chapter 7. General discussion. Scaling up antiretroviral treatment in Sub Saharan Africa: still many challenges.....</b>	<b>149</b>
7.1. When to start ART.....	149
7.2. Which first line and second line treatment.....	153
7.3. Optimal monitoring.....	155
7.4. Conclusions and recommendations.....	160
References.....	163